2022 Q1 Form 10-Q Financial Statement

#000121390022027105 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.782M
YoY Change 40.35%
% of Gross Profit
Research & Development $3.341M
YoY Change 209.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.124M
YoY Change 118.03%
Operating Profit -$5.124M
YoY Change
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$13.18K
YoY Change
Pretax Income -$5.137M
YoY Change 115.84%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.137M
YoY Change 115.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$438.7K
COMMON SHARES
Basic Shares Outstanding 11.71M shares
Diluted Shares Outstanding 11.71M shares

Balance Sheet

Concept 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.80M
YoY Change 151.2%
Cash & Equivalents $30.80M
Short-Term Investments
Other Short-Term Assets $3.949M
YoY Change 311.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $34.75M
YoY Change 162.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $34.75M
Total Long-Term Assets $0.00
Total Assets $34.75M
YoY Change 162.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $155.9K
YoY Change -40.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.187M
YoY Change -17.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.187M
Total Long-Term Liabilities $0.00
Total Liabilities $2.187M
YoY Change -40.25%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.56M
YoY Change
Total Liabilities & Shareholders Equity $34.75M
YoY Change 162.83%

Cashflow Statement

Concept 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.137M
YoY Change 115.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.045M
YoY Change 96.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -6.045M
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash $0.00
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$6.045M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001708331
CY2021Q1 us-gaap Other Income
OtherIncome
USD
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
USD
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
USD
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
USD
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
USD
CY2021Q4 vrpx Insurance Premiums
InsurancePremiums
USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2021 vrpx Weighted Average Remaining Contractual Term Years Granted
WeightedAverageRemainingContractualTermYearsGranted
CY2021Q4 vrpx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodIntrinsicValue
USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
CY2022Q1 vrpx Weighted Average Remaining Contractual Term Years Granted
WeightedAverageRemainingContractualTermYearsGranted
CY2022Q1 vrpx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodIntrinsicValue
USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
USD

Files In Submission

Name View Source Status
0001213900-22-027105-index-headers.html Edgar Link pending
0001213900-22-027105-index.html Edgar Link pending
0001213900-22-027105.txt Edgar Link pending
0001213900-22-027105-xbrl.zip Edgar Link pending
f10q0322ex31-1_virpaxpharma.htm Edgar Link pending
f10q0322ex31-2_virpaxpharma.htm Edgar Link pending
f10q0322ex32-1_virpaxpharma.htm Edgar Link pending
f10q0322ex32-2_virpaxpharma.htm Edgar Link pending
f10q0322_virpaxpharma.htm Edgar Link pending
f10q0322_virpaxpharma_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrpx-20220331.xsd Edgar Link pending
vrpx-20220331_cal.xml Edgar Link unprocessable
vrpx-20220331_def.xml Edgar Link unprocessable
vrpx-20220331_lab.xml Edgar Link unprocessable
vrpx-20220331_pre.xml Edgar Link unprocessable